Tag: Oncology

Emirates Oncology Society hosted a panel discussion to outline guidelines for diagnosis and treatment of prostate cancer

Dubai, UAE: Around 4,500 cases of cancer are reported in a year in the UAE and the country aims to bring down cancer fatalities to nearly 18 per cent by 2021. Reducing the number of deaths due to prostate cancer is one of the key performance indicators of the pillar of world-class health care of the UAE National Agenda. This was a key topic at a recently held panel discussion that focused on management of prostate cancer patients held by Emirates Urological Society.

The panel discussion witnessed the presence of several key experts. Moderating the panel discussion was Dr Humaid Al Shamsi, President of Emirates Oncology Society (EOS). He was joined by other experts including Dr Neal Shone, Dr Jawaher Ali Ansari and Dr Yasser Farhat.

“Early detection is key to managing prostate cancer. When the disease is in its initial stages (0-II), less aggressive treatment is needed, and the survival rate is almost 100 percent. However, if left undetected and allowed to progress to other areas in the body, the five-year survival rate drops significantly to 30 percent,” said Dr Shamsi.

Elaborating on the need to increase awareness about this cancer that affects men, he said, “Every male above the age of 45 must take a prostate-specific antigen (PSA) test. A PSA test is a simple blood test which is used to screen for prostate cancer, helping with early detection.”

At the panel discussion, panellists were offered an opportunity to hear directly from patients of prostate cancers. The summit focused on the often-overlooked emotional burden of the disease, with the aim of allowing the parties to establish a needs-based support programme to address ways of improving cancer patients’ day-to-day quality of life.

In addition, the discussion also highlighted UAE’s efforts in introducing advanced technology to treat cancer, as well as brought to focus latest trends, enhanced facilities and deployment of experts by the UAE which has been a key force in aiding patients with the right treatment.

Symptoms of prostate cancer usually appear during the late stages of the disease, as such experts at the panel encouraged a screening via genetic testing for men with a strong family history of cancer – such as prostate, breast, pancreatic or colon cancer – in order to better understand their risk.

-Ends-

© Press Release 2020

Source Article

Continue reading

ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting

CLEVELAND, Oct. 1, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) today announced that the Company will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting.

Event:                

Physician-led Webinar for Investors and Analysts at 2020 ASTRO Annual Meeting



Date:          

Tuesday, October 27, 2020



Time:          

9:00 a.m. – 10:00 a.m. MTN



Details:          

Registration is required to attend and will close an hour prior to the start. Please register at https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm_bmcr_source=Press. An archived replay of the meeting will be available within 24 hours on ViewRay’s investor relations website at http://investors.viewray.com/events-and-presentations/upcoming-events.



Guest Speakers:     

Dr. John Bayouth is a tenured professor and the Bhudatt Paliwal endowed chair of the Radiation Oncology Physics Division in the Department of Human Oncology at the University of Wisconsin in Madison, one of the nation’s premier radiation oncology physics programs. He is also the director of the UW–Madison Medical Physics Residency Program in Radiation Therapy. Dr. Bayouth has served in the presidential chair of both the American Association of Physics in Medicine (AAPM) and the Society of Directors of Academic Medical Physics Programs (SDAMPP) and within various committees of the American Society of Radiation Oncology (ASTRO), the Radiological Society of North America (RSNA), and the American Board of Radiology (ABR).




Daphne Haas-Kogan, MD, is Chair of the Department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center (DFBWCC) and Boston Children’s Hospital. She is also the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School. As Department Chair, her vision includes supporting each member of the Radiation Oncology Department in fostering close collaborative ties with diagnostic radiologists, medical and pediatric oncologists, surgeons, pathologists, and basic science investigators to spearhead cutting edge science, translational investigations and clinical studies, all based on the depth and breadth of success that already permeates DFBWCC. Dr. Haas-Kogan is a member of the National Academy of Medicine.

A question and answer session will be held at the end of the presentation.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades, and installations, ViewRay’s anticipated future operating and financial performance, and ViewRay’s conference calls to discuss its quarterly results. Actual results could differ from those projected in any forward-looking statements due to

Continue reading